Skip to main content
. 2020 May 12;15(3):203–210. doi: 10.1016/j.jtumed.2020.04.004

Table 4.

Drug resistance index for 67 Pseudomonas aeruginosa clinical isolates.

Number (%) Median DRI
Isolates susceptible to both ceftazidime-avibactam and ceftolozane-tazobactam 41 (61.2) 0.18
Isolates resistant to both ceftazidime-avibactam and ceftolozane-tazobactam 25 (37.3) 1
Community-acquired strains 15 (22.4) 0.63
Hospital-acquired strains 52 (77.6) 0.9

DRI: drug resistance index.